Compare AMTD & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | STIM |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 95.6M |
| IPO Year | 2019 | 2018 |
| Metric | AMTD | STIM |
|---|---|---|
| Price | $1.05 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 6.1K | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.80 |
| 52 Week High | $1.65 | $4.84 |
| Indicator | AMTD | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 56.41 |
| Support Level | $0.98 | $1.23 |
| Resistance Level | $1.07 | $1.65 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 30.00 | 75.76 |
AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.